Organogenesis Holdings Inc. announced the initiation of a BLA submission to the FDA for ReNu, a cryopreserved, amniotic suspension allograft for knee arthritis. If approved, ReNu would be the first non-surgical biologic therapy for knee osteoarthritis pain. Knee OA affects 31.1 million Americans and is projected to grow to 34.4 million by 2027. ReNu consists of amniotic fluid cells and micronized amniotic membrane components. Organogenesis plans to complete the BLA submission by the first half of 2026. The company is a leading regenerative medicine company focused on wound care and sports medicine solutions.

Read more at GlobeNewswire: Organogenesis Announces Initiation of Biologics License